News | Heart Valve Technology | August 03, 2017

4C Medical's Novel Mitral Regurgitation Repair Therapy Highlighted at Innovation Summit

Mitral Valve regurgitation (MR) showed on an echocardiogram using a Toshiba system

Aug. 3, 2017 — 4C Medical Technologies Inc. minimally invasive therapies for structural heart disease said its transcatheter therapy for mitral regurgitation (MR) was featured in the Innovation Summit at Cardiovascular Innovations (CVI) 2017 held Aug. 2, 2017 in Denver, Colo.

4C Medical is developing an MR therapy that preserves the native mitral valve and left ventricle using a supra-annular, atrial-only fixation technology. The design eliminates known issues of current transcatheter mitral valve replacement (TMVR) technologies which rely on placement and fixation in the native mitral annulus and left ventricle.

"The mitral valve anatomy is complex, with many different MR mechanisms. Current TMVR devices have experienced challenges trying to imitate surgical procedures. It is very exciting to see 4C Medical's innovative approach — positioning the implant in the left atrium above the native annulus, with no presence in the left ventricle — to simplify MR treatment and provide a therapeutic option to a broader patient population," said Philippe Généreux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute of Morristown Medical Center in Morristown, N.J., and a practicing interventional cardiologist at Hôpital du Sacré-Coeur de Montréal, Canada.

"We are honored to have been one of the five companies selected to showcase our innovation," said Robert Thatcher, CEO of 4C Medical. "Our team is dedicated to developing better options for patients with MR, and participating in the CVI Innovation Summit further validates the uniqueness of our approach."

4C Medical recently reported that it exceeded its $8 million convertible note offering goal, raising approximately $9 million that will be used to finalize the design of the technology and conduct the early feasibility study.

Mitral regurgitation (MR) is a common heart valve disease affecting nearly 10 percent of Americans aged 75 and older.[1] MR occurs when the mitral valve leaflets do not close properly and allow blood in the left ventricle to leak back into the left atrium. It is a progressive disease and if left untreated, MR can lead to atrial fibrillation, pulmonary hypertension, heart failure and death. Approximately 50 percent of patients with severe, symptomatic MR are not referred for surgery mostly due to risks associated with the procedure.2 MR not only develops with age but also affects young patients, resulting in an overall mortality rate of 50 percent at 5 years. With age, the mortality rate increases. Patients above 75 years of age experience a mortality rate of 50 percent at one year. There is a significant potential benefit for minimally invasive solutions to address the unmet clinical need for patients who are not suitable candidates for MR surgery. 

4C Medical is developing minimally invasive therapies for MR and tricuspid regurgitation. 

Read about "4C Medical's Novel Mitral Regurgitation Therapy Highlighted at TVT Innovation Forum."
 

References:

1. Nkomo VT, et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005-11. doi: 10.1016/S0140-6736(06)69208-8.

2. Mirabel M, Iung B, Baron G, et al. “What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery?” Eur Heart J. 2007;28(11):1358-65.

Related Content

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal fun
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021
May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor
April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images

Getty Images

News | Cath Lab | May 03, 2021
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for sta
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
News | Cath Lab | April 29, 2021
April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American
There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

News | Cath Lab | April 28, 2021
April 28, 2021 – Results from a retrospective observational study, presented today at...
A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell

A cardiac cath lab complex PCI case at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Cath Lab | April 28, 2021
Videos | Cath Lab | April 02, 2021
Corindus, a Siemens Healthineers company and a developer of vascular robotics, recently launched a new set of automat
Videos | Cath Lab | March 31, 2021
This is a quick example of clinical use of the Shockwave Medical Intravascular Lithotripsy system that uses sonic wav